← Leaderboards
Zhirui Wang
Rock Immune Llc
$2,400,000
Attributed
$2,400,000
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.8M · FY2021–25$2M$1.5M$1M$500K$0
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$2,400,000 · 1
By mechanism
R42$2,400,000 · 1
Top collaborators
No co-investigators on record.
Others in their field
Other Emerging Leaders on “Il2 Gene”
- Zachary Scott Morris · University Of Wisconsin-Madison$3,825,000
- Richard P Junghans · It Bio, Llc$3,250,862
- S Alice Long · Benaroya Research Inst At Virginia Mason$2,800,794
- Robert Michael Starke · University Of Miami School Of Medicine$2,419,884
- Hai-Bin Ruan · University Of Minnesota$2,330,821
- Shikhar Mehrotra · Lipo-Immuno Tech, Llc$2,224,559
Research focus
Il2 GeneIl2ra GeneAnti-Tumor Immune ResponseCancerousAnimal FacilityCc Chemokine Receptor 4Blood CellsChronic DiseaseClinical DiagnosisClinical TrialsCancer TypeCutaneous T-Cell LymphomaDenileukin DiftitoxDiphtheria ToxinDrug CandidateDrug KineticsEffective TherapyEscherichia ColiExtranodalFusion ToxinGenetic EngineeringGood Laboratory PracticeColoradoImmune Response
Grant awards (4)
CCR4-IL2 Bispecific Immunotoxin for Targeted Therapy of Cutaneous T-Cell Lymphoma$248,336
R42 · FY2025 · CA · contact PI
CCR4-IL2 Bispecific Immunotoxin for Targeted Therapy of Cutaneous T-Cell Lymphoma$875,832
R42 · FY2023 · CA · contact PI
CCR4-IL2 Bispecific Immunotoxin for Targeted Therapy of Cutaneous T-Cell Lymphoma$875,832
R42 · FY2023 · CA · contact PI
CCR4-IL2 Bispecific Immunotoxin for Targeted Therapy of Cutaneous T-Cell Lymphoma$400,000
R42 · FY2021 · CA · contact PI